RHOVAC APS

Their core work

RHOVAC is a Danish biotech SME focused on developing therapeutic cancer vaccines, specifically targeting metastatic prostate cancer through immunotherapy. Their core product, RV001, is designed to harness the immune system to attack cancer cells that have spread beyond the primary tumor — a major unmet clinical need. The company has demonstrated commercial viability through successful progression from a Phase 1 feasibility grant to a full Phase 2 SME Instrument award under Horizon 2020, suggesting meaningful technical validation. They operate as a clinical-stage or pre-clinical biotech, developing proprietary vaccine technology rather than providing services.

What they specialise in

How they've shifted over time

RHOVAC's H2020 history spans only two years (2018–2019) and both projects address the same technology — the RV001 vaccine. There is no visible shift in scientific domain; rather, the arc shows a single focused program maturing from feasibility validation (Phase 1, €50,000) to full development and demonstration (Phase 2, €2.5M). The absence of early-period keywords versus rich recent-period keywords (metastatic cancer, prostate cancer, immunotherapy, therapeutic vaccine) reflects the phase structure: Phase 1 was exploratory, Phase 2 defined the clinical and commercial scope precisely.

RHOVAC is on a single-product development trajectory — if RV001 progressed through Phase 2 successfully, the logical next step is clinical trials and partnering with larger pharma or hospital networks.

How they like to work

RHOVAC has acted exclusively as coordinator and sole beneficiary across both projects, which is characteristic of the SME Instrument funding structure — designed for individual companies to advance their own technology. This means they have no documented consortium partnerships in H2020 data, and their collaboration model is self-directed R&D rather than consortium-based research. Organizations looking to partner with them would likely engage through licensing, co-development agreements, or clinical trial partnerships rather than traditional EU consortium participation.

RHOVAC has no documented consortium partners in their H2020 portfolio, as the SME Instrument operates without multi-partner consortia. Their network is therefore not visible through EU project data and would need to be assessed through clinical, pharma, or investor channels.

What sets them apart

RHOVAC is one of very few Danish SMEs to have secured both phases of the EU SME Instrument for a single cancer vaccine program, indicating that their technology passed rigorous independent evaluation twice. Their focus on the metastatic phase of prostate cancer — rather than primary tumor treatment — addresses a specific and commercially important clinical gap where standard therapies frequently fail. For consortium builders in oncology or immunotherapy, they bring a validated, proprietary vaccine asset rather than generic research capability.

Highlights from their portfolio

• RV001
  Awarded €2.5M under the SME Instrument Phase 2 — one of the largest individual SME grants available — for clinical development of a therapeutic prostate cancer vaccine, validating both scientific merit and commercial potential.
• RV001
  The Phase 1 feasibility grant (2018) that preceded the Phase 2 award demonstrates a rare clean progression through the full SME Instrument pipeline for the same product.